Bond.az White LogoBond.az Black Logo

Nvidia Vera Rubin platform enters full production

Nvidia's Vera Rubin platform enters full production for AI systems, with global supply chain partners ramping up manufacturing.

Daniel Rodriguez
ByDaniel Rodriguez- Senior Editor
|
0

Nvidia (NASDAQ:NVDA) announced Saturday that its Vera Rubin platform is entering full production, with Taiwan's server manufacturers and global supply chain partners producing systems at scale for AI labs, cloud providers and hyperscalers.

The production ramp comes as Nvidia maintains its position as the world's most valuable semiconductor company with a market capitalization of $5.11 trillion. According to Bond.az data, the company trades below its Fair Value and maintains an excellent financial health score of 3.8 out of 5.

The Vera Rubin platform comprises five purpose-built racks operating as an integrated AI supercomputer for agentic workloads. The system unifies Vera Rubin NVL72 systems, Vera CPU, Groq 3 LPX, Vera BlueField-4 STX storage and Spectrum-6 SPX Ethernet racks.

"Agentic AI is a new kind of workload. One prompt can launch a thousand-step journey of reasoning, retrieval, tool use and response generation," said Jensen Huang, founder and CEO of Nvidia.

The platform represents the third generation of Nvidia's MGX rack-scale systems. The company stated that hundreds of supply chain partners across 350 factories in 30 countries are ramping production, including 150 partners in Taiwan.

System builders in full-scale production include Dell Technologies, HPE, Lenovo and Supermicro, along with AIC, ASRock Rack, ASUS, Foxconn, GIGABYTE, Inventec, MiTAC Computing, MSI, Pegatron, Quanta Cloud Technology, Wistron and Wiwynn.

The platform introduces Spectrum-X Ethernet Photonics, which Nvidia describes as the first co-packaged-optics-based switches with 200Gb/s SerDes now in production. CoreWeave, Lambda and Oracle Cloud Infrastructure are among the initial adopters.

The Vera Rubin platform integrates BlueField-4 DPUs with software-defined networking at speeds up to 800Gb/s. Cloud providers adopting Nvidia Confidential Computing include CoreWeave, IBM Cloud, Lambda, Microsoft Azure and Vultr.

Production shipments of Vera Rubin are scheduled to begin this fall.

More News
Today / 05:33
|
810

Genentech to Present Obesity Drug Trial Data at ADA

Genentech presents Phase II data for obesity drugs enicepatide and petrelintide at ADA conference. Latest updates on weight loss treatments.

0
Today / 04:32
|
519

Nvidia Launches Vera CPU for AI Agent Workloads

Nvidia launches Vera CPU for AI agent workloads. 88-core processor offers 1.8x speed over x86. Partners include Anthropic, OpenAI, Dell, HPE, and more.

0
Yesterday / 21:00
|
243

Berkshire Hathaway buys Taylor Morrison for $8.5B

Berkshire Hathaway acquires Taylor Morrison for $8.5 billion. The deal is expected to close in H2 2026.

0
Yesterday / 16:31
|
665

iHuman acquires two education apps for $13M

iHuman Inc. acquires All Knowledge and Perfect Lingo education apps for RMB94 million, appoints new executives.

0
Yesterday / 13:02
|
563

Revolution Medicines Phase 3 Trial Results

Revolution Medicines announces positive Phase 3 trial results for daraxonrasib in pancreatic cancer, showing significant survival benefit.

0
Yesterday / 13:01
|
802

Prostate cancer death risk cut by 20% with J&J drug

Johnson & Johnson's apalutamide reduces prostate cancer death risk by 20%, according to Phase 3 trial results.

0
Yesterday / 12:31
|
392

Brenetafusp Shows Promise in Melanoma

Immunocore's brenetafusp showed 14.3-month median overall survival in Phase 1/2 melanoma trial, supporting Phase 3 development.

0
Yesterday / 09:32
|
612

National Vision Q1 2026: margins expand

National Vision Holdings Q1 2026 financial results: revenue $543.9M, margin expansion, 4.5% comparable store sales growth.

0
2026-05-30 15:31
|
753

Mineralys Presents Lorundrostat Data in Kidney Patients

Mineralys (MLYS) reveals new clinical data for lorundrostat showing efficacy in hypertensive patients with chronic kidney disease.

0
2026-05-30 14:31
|
541

Cabometyx Cuts Neuroendocrine Tumor Risk

Exelixis announces Cabometyx reduces neuroendocrine tumor progression risk by 74% in CABINET trial. New data presented at ASCO.

0
2026-05-30 12:32
|
339

Immunome presents phase 3 trial results for desmoid tumor drug

Immunome announces phase 3 results for varegacestat in desmoid tumors: 84% reduction in progression risk, 56% objective response rate.

0
2026-05-30 07:30
|
735

Tesla Faces China Lawsuit Over Full Self-Driving Claims

Tesla faces a consumer lawsuit in China over Full Self-Driving claims. 10 vehicle owners allege misleading advertising and fraud, seeking $583,000 in damages.

0
...